Abstract
We examined the effects of the acute administration of salmon calcitonin on phosphate metabolism in tumoral calcinosis. On two different days, 200 MRC U of the synthetic hormone were administered sc to a 38-year-old patient, either as twice daily 100 MRC U injections, or as a continuous sc infusion via a portable pump. Both ways of calcitonin administration elicited a Phosphaturic effect and a lowering of serum phosphate level comparable with that observed after an iv infusion of calcitonin. 1,25 dihydroxyvitamin D level, which was in the normal range during a control study, increased after calcitonin administration. In our patient, long term therapy with diet, a phosphate-binding agent and calcitonin prevented the occurrence of new ectopic calcifications. Owing to its Phosphaturic activity, synthetic salmon calcitonin may be a useful adjunct to diet and aluminium-containing antacids in long-term management of tumoral calcinosis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Duret M.H. Tumeurs multiples et singulieres des bourses sereuses. Bull. Soc. Anatom. Paris 74: 725, 1899.
Inclan A. Tumoral calcinosis. JAMA 121: 490, 1943.
Lyles K.W., Burkes E.J., Ellis G.J., Lucas K.J., Dolan E.A., Drezner M.K. Genetic transmission of tumoral calcinosis: autosomal dominant with variable clinical expressivity. J. Clin. Endocrinol. Metab. 60: 1093, 1985.
Prince M.J., Shaefer P.C., Goldsmith R.S., Chausmer A.B. Hyperphosphatemic tumoral calcinosis. Association with elevation of serum 1,25 dihydroxycholecalciferol concentrations. Ann. Intern. Med. 96: 586, 1982.
Hunter I.P., MacDonald D.G., Ferguson M.M. Developmental abnormalities of the dentin and pulp associated with tumoral calcinosis. Br. Dent. J. 135: 543, 1973.
Zerwekh J.E., Sanders L.A., Townsend J., Pak C.Y.C. Tumoral calcinosis: evidence for concurrent defects in renal tubular phosphorus transport and in 1,25 dihydroxycholecalciferol synthesis. Calcif. Tissue Int. 32: 1, 1980.
Mitnick P.D., Goldfarb S., Slatopolsky E., Lemann J., Gray R.W., Agus Z.S. Calcium and phosphate metabolism in tumoral calcinosis. Ann. Intern. Med. 92: 482, 1980.
Lufkin E.G., Kumar R., Heath H. Hyperphosphatemic tumoral calcinosis: Effects of phosphate depletion on vitamin D metabolism, and of acute hypocalcemia on parathyroid hormone secretion and action. J. Clin. Endocrinol. Metab. 56: 1319, 1983.
Salvi A., Cerudelli B., Cimino A., Zuccato F., Giustina G. Phosphaturic action of calcitonin in pseudotumoral calcinosis. Horm. Metab. Res. 15: 260, 1983.
Mozzaffarian G., Lafferty F.W., Pearson O.H. Treatment of tumoral calcinosis with phosphorus deprivation. Ann. Intern. Med. 77: 741, 1972.
Tartarotti D., Adami S., Galvani G., Dorizzi R., Piemonte G., Lo Cascio V. Simultaneous measurement of 1,25-dyhydroxy-vitamin D, 24,25-dyhydroxy-vitamin D and 25-hydroxy-vitamin D from a single two milliliters serum specimen. Preliminary clinical application. J. Endocrinol. Invest. 7: 545, 1984.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Candrina, R., Cerudelli, B., Braga, V. et al. Effects of the acute subcutaneous administration of synthetic salmon calcitonin in tumoral calcinosis. J Endocrinol Invest 12, 55–57 (1989). https://doi.org/10.1007/BF03349921
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03349921